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with chronic periodontitis: a randomized 
double-blind, placebo-controlled clinical trial
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Abstract 
Background: Yunu‑Jian (YJ) is a Chinese medicine (CM) heat purging formula, which is used to reduce wei huo 
(stomach‑heat, SH) and enrich shen yin (kidney‑yin, KY). This formula is also commonly used to manage diabetes 
mellitus and gum/oral inflammation. The activity of YJ can be modified or refined by the addition of other CM herbs 
and/or minor changes to one of its five key ingredients. The aim of this study was to evaluate the adjunctive use of 
modified YJ (mYJ) or YJ containing additional osteoblast‑stimulating and inflammation‑modulating CM herbs in the 
non‑surgical periodontal treatment of smokers with chronic periodontitis in a randomized, double‑blind, prospective, 
placebo‑controlled study.
Methods: Healthy adult male smokers with untreated chronic periodontitis who showed CM syndrome of SH and 
KY deficiency (KYD) whilst attending a dental teaching hospital from October to December, 2005, were invited to 
participate in a randomized double‑blind, placebo‑controlled clinical trial. The trial itself involved the once‑daily oral 
administration of a placebo or mYJ for 3 months as an adjunct to non‑surgical periodontal therapy. Several periodon‑
tal parameters, including radiographic alveolar bone density, were measured by computer‑assisted densitometric 
image analysis (CADIA) on selected sites, and CM signs of SH and KYD were followed from their baseline values to vari‑
ous time points up to 12 months or the end of study.
Results: Twenty‑five smokers (consumed 25.0 ± 15.3 smoking‑pack years, ranged 7.5–80; aged 46.3 ± 6.8 years) 
with periodontitis and SH and KYD were recruited (Placebo, n = 14; mYJ, n = 11). All of the participants showed good 
tolerance towards the CM recipe. All of the periodontal parameters had improved after 12‑month follow‑up, and no 
statistically significant differences were detected between the control group and test group, except for the higher 
CADIA values observed compared with the baseline at 12 months for test sites (P = 0.025). 4/3/3 test vs 14/13/13 
control participants had persisting SH and KYD at 6, 9 and 12 months (P < 0.001), respectively.
Conclusions: The adjunctive use of mYJ preserved the post‑treatment increases in the radiographic alveolar bone 
density at the study sites and led to an overall improvement in SH and KYD compared with the controls.
Trial registration HKU Clinical Trial Register, HKCTR‑1848 (www.hkuctr.com/Study/Show/3acbf983831244d29d50b5435
40bf6e9)
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Background
Periodontal disease is an infectious disease that affects 
the periodontium of susceptible hosts, and is charac-
terized by the inflammation and destruction of the sur-
rounding tooth-supporting tissues [1]. Approximately 
20 % of the adult population of Hong Kong has a probing 
pocket depth (PPD) ≥6 mm [2]. Although bacteria play 
a critical role in the life cycle of this disease, they are not 
solely responsible for the onset of this disease, with host 
factors playing an important role in the outcome of this 
disease [3]. Smoking is one of the greatest risk factors for 
periodontitis [4, 5], and is associated with an increased 
risk of periodontal attachment loss [2, 6]. Although rou-
tine non-surgical periodontal therapy has been shown 
to be effective for the treatment of chronic periodon-
titis in smokers, smokers tend to exhibit more residual 
periodontal pockets [7–9] than non-smokers. Smokers 
also show a greater tendency towards progressive radio-
graphic alveolar bone loss despite post-treatment peri-
odontal maintenance care [10].
In the conceptual context of Chinese medicine (CM), 
periodontal disease is mainly categorized as ya xuan 
(gaping gums), ya lou (leaking gums) and ya nu (bleed-
ing gums) [11, 12]. The recommended treatment for this 
disease involves the mechanical removal of deposits from 
the affected teeth [13, 14]. The use of herbal medicine 
recipes has also been suggested to rectify the disease-
associated imbalance in the human body along the four 
major philosophical frameworks, including attention to 
poor oral hygiene, wei huo (stomach-heat, SH), shen yin 
xu (kidney-yin deficiency, KYD) and weakness in qi and 
xue (blood) [15]. The concept of CM dictates that the kid-
ney dominates the gu (bone) and sheng sui (create mar-
row) and that the kidney therefore also dominates the 
teeth, whereas the pi (spleen) and stomach meridians 
pass through the teeth and gum. Accordingly, periodon-
tal disease could therefore be a problem associated with 
unwanted changes to the homeostasis in the spleen and 
stomach or kidney [14]. From the perspective of CM, 
smoking would not only affect the lungs and airways, but 
would also fire up the qi, destroy blood and consume yin 
fluids [16].
Several CM formula have been used to treat ya xuan, 
ya lou and ya nu, including Radix Achyranthis bidenta-
tae (Huai Ni Xi), Rhizoma Drynariae (Gu Su Bu), Radix 
Ophiopogonis (Mai Men Dong), Cortex Phellodendri 
(Huang Bai) and Radix et Rhizoma Rehmanniae (Sheng 
Di Huang). All of these recipes have been reported to 
attenuate in  vivo inflammation, enhance immune func-
tion and/or modulate bone homeostasis [17, 18]. Rhi-
zoma Drynariae and Rehmannia glutinosa (Shu Di 
Huang) has also been reported to exhibit therapeutic 
effects towards bone fracture healing, including the 
induction of proliferation and osteogenic differentiation 
of human bone mesenchymal stem cells [19, 20]. Rhi-
zoma Drynariae, which contains naringin as its main 
effective component, is one of the most widely investi-
gated of all of these herbal preparations [20].
Yunu-Jian (YJ), which is also known as Jade maiden/
women decoction, Fair maiden decoction or Rehmannia 
and gypsum combination, is a CM heat purging formula 
used to reduce stomach-heat (SH) and enrich kidney-yin 
(KY) [13]. This formula is also commonly used to manage 
diabetes mellitus and gum/oral inflammation. In terms of 
the different concepts of CM, the regular smoking of ciga-
rettes leads to the burning of the stomach and fei (lung) 
[21], placing the affected individual at a higher risk of 
experiencing ya xuan due to SH. The activity of YJ can be 
modified or refined by the addition of CM herbs and/or 
minor changes to one of its five key ingredients. The aim 
of this study was to explore the adjunctive effect of using 
a specifically modified YJ (mYJ) formulation (Table 1) to 
target SH and KYD in male smokers with chronic peri-
odontitis. In terms of its modification, Rhizoma Drynar-
iae, Cortex Phellodendri and Radix Puerariae (Ge Gen; to 
promote circulation and increase blood flow) were added 
to YJ, whereas Rehmannia glutinosa was replaced with 
Radix et Rhizoma Rehmanniae. Overall, this study applied 
the CM ya xuan treatment philosophy to achieve host 
modulation in contemporary periodontal therapy [18].
In recent years, over-the-counter CM preparations 
such as Guchi-Jianzhou granules, Guchi pills (or Guchi 
Wan), Guchi extract and Yazhou Baidu powders have 
been developed to aid in the management of chronic 
periodontitis [18]. Despite the increasing availability of 
potential adjunctive agents, there have been very few 
properly designed CM-periodontal clinical trials or 
reports pertaining to the correct clinical usage of these 
preparations or formulae.
Non-surgical mechanical therapy can be effective for 
the treatment of periodontitis [22]. Smokers, however, 
have been repeatedly shown to experience inferior heal-
ing responses following non-surgical periodontal therapy 
[7, 9]. Clinicians have attempted a variety of approaches, 
including adjunctive antibiotics [23], toothpastes con-
taining triclosan/copolymers in an un-blinded fashion 
[24], and Er:YAG lasers, in place of regular mechanical 
therapy [25] to enhance or augment non-surgical perio-
dontal healing in smokers. Unfortunately, however, none 
of these efforts have produced satisfactory results.
This study aimed to evaluate the adjunctive use of 
mYJ (Table  1) for the non-surgical periodontal treat-
ment of male smokers with chronic periodontitis in a 
randomized, double blind, prospective, placebo-con-
trolled study. Middle-aged male smokers who had been 
diagnosed with CM syndrome of SH and/or KYD, but 
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were otherwise healthy, were recruited into this trial. 
Full-mouth clinical treatment responses were meas-
ured, together with radiographic treatment outcomes 
at selected sites, which were measured by computer-
assisted densitometric image analysis (CADIA) and gin-
gival crevicular fluid (GCF) volume. Digital subtraction 
radiography (DSR) was used to supplement the peri-
odontal healing response assessment as described before 
[26], which is considered as a sensitive follow-up pro-
tocol for alveolar bone healing after periodontal treat-
ment [27, 28]. General CM signs of SH and KYD were 
recorded over a 12-month study period. Standard clinical 
and radiographical periodontal parameters were followed 
throughout the clinical trial to provide an indication of 
the reduction in the periodontal inflammation (reduction 
of bleeding on probing or BOP), resolution/remodeling 
of the diseased periodontium (reduction of PPD) and 
bony repair (increase in radiographic periodontal bone 
density) [29]. As the monitoring of changes in the key 
CM syndrome of participants during a CM clinical trial 
was deemed necessary [30], and the current study was 
conducted accordingly.
Methods
Ethics
The research protocol was approved by the Ethics Com-
mittee, Faculty of Dentistry, The University of Hong Kong 
(HKU) (1/8/12d) (Additional file 1). Interested individu-
als were verbally briefed about the nature and details of 
the study with the aid of written explanatory notes cov-
ering for any potential risks or benefits from participat-
ing. They were given 1 week to think about the project 
and were advised to discuss participation with family 
members, referring doctors or dentists before return-
ing to the Periodontology Clinic, HKU and expressing 
whether to part-take the study or not. On both occasions 
they were invited to ask as many questions as they liked 
and the person responsible (PSC) took as long as needed 
to answer all issues raised. Written informed consent 
(Additional file 1) was obtained from all participants.
Study design
This study was conducted as a prospective, randomized, 
double-blinded, placebo-controlled clinical trial. Partici-
pants were randomized into control and test groups as 
follows. All enrolled individuals diagnosed with SH and/
or KYD received non-surgical periodontal therapy over 
four appointments (i.e., four times, each time a quad-
rant or upper/lower, left/right quarter of mouth treated) 
completed in a 3-week period. All of the participants 
received an oral once-daily dose of mYJ or placebo for 
3 months, followed by regular post-treatment recalls 
for up to 12 months (i.e., the end of study or 11 months 
post-periodontal treatment completion) (Fig.  1). A pla-
cebo powder (total 25 g) with a similar physical appear-
ance and taste to mYJ was prepared using several inactive 
components, including starch, glucose and Momordica 
charantia or Ku Gua (2 g), which was used as a naturally 
bitter component.
CM formula preparation
A mYJ, which contained eight Chinese medicinal ingre-
dients, was used (Table 1). The mYJ or placebo were pro-
duced in dissolvable powder form by a registered CM 
manufacturer in Hong Kong (Eu Yan Sang [Hong Kong] 
Limited). In brief, correct amounts of all raw materials 
were boiled together in water to extract their ingredi-
ents. The aqueous extract was then concentrated, dried, 
and crushed into fine powder. The correct amount of 
powder was then packed into an individually sealed plain 
aluminum sachet (25  g). A placebo powder (total 25  g) 
was packed in the similar aluminum sachets as the active 
recipe. The placebo or active sachet was coded as PH001 
or PH002, respectively by the manufacturer. The iden-
tity of the sachets was kept by one of the authors (KYZ) 
who did not participate in the collection and analysis of 
the data. Contamination screening against heavy metals, 
pesticides, and aflatoxins in both the active and placebo 
sachets was performed by an independent laboratory to 
ensure safety before human consumption. All CM agent 
preparation and toxicity testing were completed by Sep-
tember 2004.
Sample size determination
This clinical study targeted males with chronic peri-
odontitis, who were otherwise healthy (self-assessment), 
Table 1 Composition of modified Yunu-Jian (mYJ) and pla-
cebo
a Weight equivalent of the raw ingredient per preparation
b Together with Rehmannia glutinosa (Gaetn.) Libosch. Ex Fisch. Et Mey. (20 g raw 
ingredient per preparation) constituted the original Yunu-Jian recipe
Chinese name Pharmaceutical name g/daya
Yunu-Jian Rehmannia and gypsum combination
Shi Gaob Gypsum Fibrosum 25
Sheng Di Huang Radix et Rhizoma Rehmanniae 20
Mai Men Dongb Radix Ophiopogonis 18
Zhi Mub Rhizoma Anemarrhenae 15
Huai Niu Xib Radix Achyranthis Bidentatae 15
Gu Sui Bu Rhizoma Drynariae 15
Huang Bo Cortex Phellodendri 10
Ge Gen Radix Puerariae 15
Placebo
 Ku Gua Momordica Charantia 20
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except for the fact that they had been diagnosed with SH 
and/or KYD syndrome. Changes in the CADIA value 
were considered as the primary dependent variable. The 
sample size for this study was computed according to the 
following formula [31]:
where n  =  sample size, σ2  =  variance, δ  =  expected 
difference, Zα⁄2  =  1.96 if α  =  0.05, Zβ  =  0.842 if 
power = 80 %.
In a study involving non-smokers from the same local 
population, participants with chronic periodontitis 
showed changes of 60  ±  25 in their CADIA values at 
12 months after non-surgical therapy [26]. We assumed 
that the SD would be the same for smokers as it was for 
the non-smokers in this previous study. We also assumed 
that there would be an increase of 30 units (expected dif-
ference or δ) in the CADIA value at the diseased sites 
between smokers taking the placebo compared with 
those taking mYJ. Based on these assumptions, the above 
formula indicated that 10.9 or 11 participants would be 
required in each group to enable a difference of 30 units 
in the CADIA values to be detected.
Participant selection and screening
New male participants attending the Reception Clinic, 
Prince Philip Dental Hospital (PPDH), Faculty of Den-
tistry, The University of Hong Kong and satisfying the 
inclusion criteria were recruited to participate in the 
study. The target sample size was at least 14 participants 
n =
[
2σ 2
(
Zα/2 + Zβ
)2]
/δ2
each for control and treatment group, to allow for 
retention of 11 individuals in each group at 12 months. 
For inclusion, participants had to be reportedly free of 
systemic disease, and displaying the following features: 
(1) 36- to 64-years-old ethnic Chinese with untreated 
chronic periodontitis; (2) smokers with a current con-
sumption of ≥10 cigarettes per day for at least 10 years 
and expressing no interest in quitting smoking in the 
coming 12  months; (3) at least 16 standing teeth, with 
at least 1 tooth having PPD ≥5  mm in each quadrant, 
excluding the third molars; (4) radiographic evidence of 
alveolar bone loss at a proximal site up to one-third of 
root length in at least two teeth per quadrant; and (5) 
diagnosed as showing signs of SH and/or KYD CM syn-
drome (Additional file  2: Table S1). Participants were 
excluded if the initial interview revealed: (1) systemic 
disease history; (2) history of taking systemic antibi-
otics in the preceding 30  days; (3) history of any den-
tal treatment, other than oral hygiene instructions, in 
the preceding 30  days; (4) known hypersensitivity to 
any Chinese medicine in particular to any ingredients 
of mYJ or control recipe used in this study; (5) history 
of rheumatic fever or other conditions for which anti-
biotic prophylaxis prior to periodontal examination or 
invasive dental treatment might be advisable; (6) under-
going concurrent dental therapy such as orthodontic 
treatment.
Thirty two individuals satisfying the inclusion criteria 
were recruited by the end of a 3-month period (October 
to December 2005) while the whole study was finished 
approximately 12 months later.
Consent,
Baseline Examination,
Radiographs 
Recall  
0-month 9-month6-month3-month 12-month
1m1wk 4m2m 7m5m 10m8m 11m
Examination &
Radiographs
Examination &
Radiographs
Examination &
Radiographs
Examination &
Radiographs
CM treatment
3 months
Periodontal
treatment
3 weeks
Fig. 1 Study design
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Participant management and non-surgical mechanical 
periodontal treatment
This clinical study was carried out at the Periodontol-
ogy Clinic, PPDH, Faculty of Dentistry, HKU, China. A 
member of the research team (JCSH) evaluated the den-
tal eligibility of male smokers presenting at the clinic 
with untreated chronic periodontitis. Male smokers sat-
isfying the eligibility requirements were asked whether 
they would like to participate in this study, and the CM 
eligibility of those who accepted the invitation was con-
firmed by PSC. Eligible participants were then assigned 
a numerical personal identification code (study number) 
as a personal identifier to be used throughout the study 
(Fig. 2). JCSH then followed up with all of the eligible par-
ticipants to ensure that all of the necessary pre-treatment 
processes had been conducted. Emergency treatments 
such as extractions, caries stabilization and initial endo-
dontic therapy were completed prior to the commence-
ment of the non-surgical periodontal treatment trial.
After the required number of participants had been 
secured, receptionists at the Periodontology Clinic, 
PPDH, were instructed by KYZ via a concealed enve-
lope, which was prepared prior to the recruitment pro-
cess, to arrange appointments with all of the participants. 
Each envelope also included a predetermined table with 
a study number against randomized blocks indicating 
sachet allocation. Critically, the attending receptionists 
were completely unaware of the contents of the differ-
ent sachets. All of the participants signed an informed 
consent form at their first appointment and were 
subsequently presented with seven designated sachets 
with specific instruction to take one sachet per day for 
the week prior to the commencement of the non-surgical 
periodontal therapy. On the first day of the non-surgical 
periodontal therapy, each participant was presented 
with 23 identical sachets to those that they had already 
received. The participants were subsequently presented 
with 30 more of the same sachets at onw and 2 months 
after the commencement of the non-surgical periodontal 
therapy. KYZ was responsible for concealing the details 
of each participant’s allocation, whilst simultaneously 
refrained from contact with any of the participants, 
receptionists or clinicians involved in the study until it 
reached completion.
Each participant was instructed to start consuming 
the content of the allocated sachets 1 week before start-
ing the non-surgical periodontal therapy process. The 
participants were instructed to dissolve the powder in 
each sachet in 200 mL of hot water and drink the result-
ing solution while it was still warm at the beginning of 
each day. Each participant was issued with a total of 90 
sachets. Self-completion compliance sheets were given 
to each participant, when CM sachets were issued, to be 
completed at predefined intervals, including (1) within 
the 1  week pre-periodontal treatment period; (2) from 
day 8–day 30 after commencement of the periodon-
tal treatment; and (3) over the second and third month 
study period. These forms were provided to encourage 
proper CM medication consumption and to monitor 
self-reported compliance. Participants had to sign the 
Fig. 2 Flow of participants through each stage of the randomized trial
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compliance sheets to confirm their medication consump-
tion and return the sheet, together with any untaken CM 
medication, according to the schedule set. On each com-
pliance sheet, there was a section for participants to fill 
in the date, time and type of any suspected adverse effect 
experienced. Two phone numbers (accessible to PSC or 
JCSH anytime during the study period concerned) were 
written on the compliance sheet in case any participant 
wanted to contact the investigation team.
The receptionists at the Periodontology Clinic were 
instructed to arrange the non-surgical periodontal treat-
ment appointments (4 visits) within a 3-week period for 
all of the participants. The appointments were subse-
quently delivered by JCSH, who was not involved in the 
clinical data collection. All of the participants received 
the same non-surgical periodontal treatment, together 
with the same oral hygiene instructions regarding brush-
ing and interdental cleaning, followed by quadrant-
wise scaling and root surface debridement under local 
anesthesia.
Recall appointments were scheduled once every week 
for the first month after the periodontal treatment, with 
reduced frequencies thereafter (i.e., once a week at month 
2; once every 2 weeks for month 3, and once every month 
until the end of study). Oral hygiene reinforcement and 
motivation were provided as necessary. Supra- and sub-
gingival debridement was performed if needed during 
the recall appointments. Clinical and radiographic exam-
inations were carried out at the 3-, 6-, 9- and 12-month 
recall visits.
Any residual periodontal problems detected at the con-
clusion of the study at the 12-month recall, namely any 
sites with residual PPD  >5  mm, were followed-up with 
an appropriate periodontal treatment process (e.g., re-
root planing or access surgery), which was arranged and 
delivered without delay. All of the participants were again 
reminded of the deleterious effects resulting from their 
continued smoking and were advised to quit smoking at 
all of the recall appointments and at the end of the clini-
cal trial.
Clinical examination
Several clinical parameters were recorded at the baseline, 
as well as being recorded at 3, 6, 9 and 12 months after 
enrollment. All of the clinical examinations were per-
formed by one calibrated examiner (SMLL).
The PPD and probing attachment level (PAL) meas-
urements were recorded at six different sites for each 
tooth, excluding the third molars (i.e., the mesio-buccal, 
mid-buccal, disto-buccal, mesio-lingual, mid-lingual and 
disto-lingual sites). Custom-made poly-ethylene occlusal 
stents were fabricated for each participant as reference 
guides to ensure the reproducibility of the probing sites 
and for measuring the probing attachment level through-
out the study using a manual periodontal probe (PCP-
UNC 15, Hu-Friedy probe®, Chicago, IL, USA). The 
presence of any plaque was recorded dichotomously as 
the presence or absence of plaque according to the detec-
tion of plaque deposits determined by running the tip of 
the periodontal probe along the tooth surface at the gin-
gival margin of each site. BOP was designated as positive 
if bleeding occurred within 10 s of periodontal probing.
Radiographic examinations were carried out at the 
two deepest proximal single-root tooth-sites in each 
participant. The two deepest non-neighboring sites 
(PPD ≥ 5 mm) of the mouth on two individual teeth with 
well-defined angular defects were selected as described 
previously [26]. The sites were selected initially from the 
panoramic oral radiograph taken as part of the PPDH 
admission screening procedure and subsequently con-
firmed by paralleling periapical radiographs. The gingival 
crevicular fluid volumes of these sites were also recorded 
(last paragraph of this section).
Radiographic examinations for following up any 
changes in alveolar bone by standardized DSR were car-
ried out as described by Woo et  al. [29] and Lai et  al. 
[26]. Briefly, after selecting suitable sites for follow up, 
a custom-made acrylic bite block attached to a Rinn 
XCP film holder (Rinn Corporation, Elgin, IL, USA) 
was constructed for each of the selected sites to pro-
duce standardized reproducible periapical radiographs 
for digital subtraction [32]. Rectangular and long cone 
techniques were used with a radiographic film requiring 
a short exposure time (Kodak Insight, Eastman Kodak 
Co., Rochester, NY, USA) to minimize the level of radio-
graphic exposure to the participant. The X-ray cone was 
also modified to allow for the rigid attachment of the 
bite block to the cone. As a consequence, the angulations 
between the X-ray source, the object and the film were 
reproducible. All periapical radiographs were taken using 
the paralleling technique with the same X-ray machine 
(GE 700, General Electric Co., Fairfield, CT, USA) using 
the same settings (70 kV, 15 mA). The size-1 radiographic 
films were used for the anterior regions, where size-2 
radiographic films were used for the posterior regions 
to minimize the distortion of the films. All of the films 
were developed in a batch with an automatic developing 
machine (Periomat, Dürr Dental, Bietigheim-Bissingen, 
Germany) to reduce variability during the developing 
process.
All of the radiographs were subsequently scanned into 
a computer at 600 dpi with a flatbed scanner equipped 
with a transparency module (Agfa Studiostar, Agfa 
Gaevert, Mortsel, Belgium). The images were imported 
into software based on the Linux system. Selected 
sites were defined as regions of interest (ROI) on the 
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radiographs, and the CADIA values were calculated for 
each ROI according to a previously reported formula 
[27]. The CADIA values were used to quantify changes 
in the alveolar bone and were presented as the net val-
ues of two standardized radiographic images, which were 
recorded at different time points [26].
GCF sampling was conducted according to the proce-
dure reported by Jin et al. [33]. Briefly, for a subject tooth 
(same sites as the DSR study), after isolation with a cotton 
roll and the removal of the supragingival plaque, a stand-
ard filter GCF strip (Periopaper® GCF strips, IDE Inter-
state, Amityville, NY, USA) was inserted into the gingival 
crevice or pockets until mild resistance was felt. The GCF 
strip was then left in place for 30 s. The amount of GCF 
collected was represented by the electric conductance, 
which was measured immediately using a GCF meter 
(Periotron 8000, IDE Interstate). The electrode jaws of 
the GCF meter were cleaned and dried after each meas-
urement with the machine reading set to zero. The GCF 
volumes of two periodontitis-free sites were also followed 
in each participant, preferably from the same tooth type 
as the diseased tooth of interest. The GCF volumes from 
each sample site were calculated based on their electric 
conductance readings, which were measured using a 
Periotron 8000 GFC meter, as described previously [33]. 
Clinical data collection for the last participant was com-
pleted in December 2006.
Data analysis
Data analysis was carried out using the statistics soft-
ware: SPSS (SPSS 16.0, Chicago, IL, USA). Simple 
descriptive statistics were used to summarize the vari-
ables studied. Variations in demographic data and smok-
ing habits between control and test groups were assessed 
by unpaired t tests. Variations in CM signs between con-
trol and test groups were assessed by Fisher’s exact test. 
Change of participants’ CM syndrome over time was 
assessed by Chi square test for trend.
As the normality (Kolmogorow-Smirnoff test) and 
homoscedasticity assumptions (Levene test) of the fol-
lowing data appeared to be valid, clinical parameters, 
including changes in CADIA, PAL, PPD, Pl % and BOP % 
were analyzed by repeated measures analysis of variance 
(ANOVA) with Dunnett’s post-test. Significance level 
was set as α < 0.05.
Results
Eight of the 40 participants were considered ineligible by 
the CM practitioner because their CM signs and symp-
toms did not fit with the inclusion criteria. A total of 40 
male smokers with chronic periodontitis were screened, 
and 32 met the inclusion criteria and were arbitrarily 
allocated (Fig.  2). Seventeen participants were assigned 
to receive PH001 (placebo), with the remaining 15 being 
assigned to receive PH002 (mYJ). A total of 7 (21.9  %) 
participants dropped out from the trial during the study 
period: 2 (11.8  %) and 3 (20.0  %) participants withdrew 
from the placebo and CM groups, respectively, because 
they believed that they had recovered already, while 1 
participant from each group did not complete the trial 
because they left Hong Kong (Fig. 2).
The baseline characteristics of the participants are 
summarized in Table  2. No significant differences were 
observed between the two groups. The full-mouth peri-
odontal parameters collected for all of the participants 
over the entire study period are shown in Fig.  3a–d. 
The results revealed that both groups showed improved 
plaque control and gingival inflammation (reflected by 
BOP % reduction) at 3 and 6 months post treatment com-
mencement. However, the levels of plaque and the clini-
cal signs of periodontal tissue inflammation appeared 
to increase beyond this point in both groups. The mean 
PPD and PAL values improved and became stable at 
6–9  months, although the mean PPD value showed a 
tendency towards the baseline level at 12  months. No 
differences were observed in the mean Pl %, BOP % and 
PPD values between the test and control groups at any 
of the follow-up time points. Furthermore, the changes 
observed in the mean PAL over time were not signifi-
cant for either of the groups compared with the baseline, 
except at 12  months, where we observed a significant 
improvement in PAL compared with the baseline in the 
control participants (Fig. 3d).
All of the participants exhibited good tolerance to the 
study medicines, with none of the participants report-
ing any adverse effects. The overall compliance with the 
dose regimen was also good. According to the compli-
ance sheets, all of the participants completed their course 
of herbal medicine, except for one participant who failed 
to attend the scheduled appointment and was therefore 
unable to collect the prepared medicine on time. In this 
particular case, the participant missed 2 weeks of CM 
medication during the third month. This participant was 
subsequently determined to be a control group partici-
pant, and was allowed to remain in the study.
The efficacy of the CM was noted (Fig. 4). The determi-
nation of SH syndrome can be subjective because of vari-
ations in the severity of the swelling and gum pain, thirst, 
halitosis, apatite, constipation and long bi (short urine) or 
dribbling urination [34]. The determination of KYD syn-
drome can also be subjective because of variations in the 
severity of the soreness of waist, backache, hot flushes 
and night sweating (gu zheng or steaming bone), mobile 
teeth, hair loss, dryness of the mouth and throat, dizzi-
ness, tinnitus and deafness, wasting, insomnia, forgetful-
ness, while CM tongue and pulse signs are objectively 
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accessed (Additional file  2: Table S1). The administra-
tion of a placebo during the non-surgical periodontal 
therapy led to the remission of KYD or SH syndrome 
in no more than half of the control group participants 
as early as 2 or 9  months after the commencement of 
the therapy, respectively. However, the use of mYJ as an 
adjunctive therapy for the treatment of non-surgical peri-
odontal led to the remission of KYD and SH syndrome in 
approximately 80 % of the participants evaluated in this 
trial (Fig.  4). These effects were particularly prominent 
at 6 and 9  months post-treatment commencement for 
KYD and SH syndrome, respectively, and remained low 
at 12 months. Notably, only 1 out of the 14 participants 
in the control group showed total remission for the CM 
syndrome of SH/KYD at the end of the study, whereas 
complete CM syndrome resolutions were observed in 
8 out of the 11 participant in the mYJ treatment group 
(Fig. 4c).
Data pertaining to the selected periodontitis sites eval-
uated throughout this study are summarized in Fig.  5. 
Plaque control improved considerably at these periodon-
titis sites after the therapy, although the reoccurrence of 
some plaque was observed at the end of the study (i.e., at 
12 months). A similar outcome was also observed for the 
percentage of sites with BOP and PAL. It is noteworthy 
that the mean depth of selected pockets sites in the mYJ 
group appeared significantly greater than that of the pla-
cebo group (P = 0.02, unpaired t test, Fig. 5a, b). The GCF 
volumes (µL/30  s paper strip sampling) of the selected 
sites remained low after the treatment process (Fig. 5c), 
with the corresponding GCF volumes of the periodonti-
tis-free sites from the reference teeth on the same partici-
pant remained at a low level of 0.018–0.074 µL at every 
time point. Significant improvements were observed in 
the changes in the mean CADIA values at selected sites 
in the mYJ group participants at 12  months (Fig.  5d). 
Similar improvements were not observed in the control 
group.
Discussion
Research towards the use of CM as adjunctive therapies 
in contemporary periodontal treatment appears to pro-
gressing slowly [17]. The symptoms of CM syndrome in 
patients suffering with periodontitis include stomach-
heat, kidney-yin deficiency and weakness in the qi and 
blood [15, 35, 36]. Of the male smokers diagnosed with 
chronic periodontitis prior to this study, 80 % were also 
diagnosed with SH and KYD syndrome and were conse-
quently invited to participate in our clinical trial (Fig. 2). 
Zhang et al. [37] reported that 27.8 % of the participants 
in their cohort study of 26 mild, 41 moderate and 23 
severe conveniently recruited periodontitis participants 
Table 2 Demography, pre-treatment clinical and CADIA sites profiles of participants
BOP bleeding on probing, PAL probing attachment level, PPD probing pocket depth
a Upper/lower teeth (total)
Characteristic Categories Placebo (n = 14) mYJ (n = 11) Test Statistics P value
Age mean ± SD 43.6 ± 7.6 49.0 ± 5.0 t 2.0317 0.0539
Smoking habit (self-reported)
Baseline Smoked years 22.4 ± 7.7 25.0 ± 8.1 t 0.8193 0.4210
Cigarettes/day 20.0 ± 9.2 22.3 ± 8.2 t 0.6502 0.5220
Pack‑years 22.2 ± 11.0 30.2 ± 21.4 t 1.2140 0.2371
End of study Cigarettes/day 18.6 ± 7.6 21.4 ± 7.8 t 0.9040 0.3754
Full‑mouth parameter
Standing teeth mean ± SD 23.1 ± 3.5 21.4 ± 3.2 t 1.272 0.2166
Plaque  % mean ± SD 89.4 ± 4.4 88.3 ± 7.1 t 0.3991 0.6954
BOP % mean ± SD 83.7 ± 11.9 86.8 ± 13.2 t 0.6085 0.5497
% PPD ≥ 5 mm mean ± SD 42.7 ± 19.4 44.6 ± 20.1 t 0.2382 0.8140
% PAL ≥ 7 mm mean ± SD 80.6 ± 13.1 73.3 ± 21.0 t 1.009 0.3290
CADIA sites (2/participant)
Tooth type Incisor 8/0 (8)a 6/1 (7) χ2 2.487 0.2884
Canine 7/5 (12) 3/2 (5)
Premolar 4/4 (8) 5/5 (10)
Plaque  % 100 100
BOP % 90.8 96.1 χ2 1.255 0.2626
PPD mean ± SD 6.17 ± 1.68 6.33 ± 1.23 t 0.592 0.5598
PAL mean ± SD 9.86 ± 2.23 9.02 ± 1.53 t 1.066 0.2977
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(50  % female, unknown smoking habit) were diagnosed 
to have SH and KYD. The results of a subsequent study 
by the same group based on a similar group of conveni-
ently recruited periodontitis patients (52.5  % female, 
unknown smoking habit) revealed that half of the partici-
pants experienced kidney deficiency syndrome [35]. Both 
of these studies showed a lower prevalence of SH and 
KYD than our current cohort. This difference was attrib-
uted to the fact that it was relatively easy to recruit and 
secure our trial sample size, especially male smokers with 
severe chronic periodontitis. However, a more in depth 
population study would be required to fully establish the 
relationship between severe chronic periodontitis and SH 
and/or KYD.
This study was therefore deigned to evaluate the effects 
of mYJ on the proximal periodontal radiographic alveo-
lar bone density using the CADIA values as the primary 
dependent variable following therapy. In line with results 
from previous trials involving smokers treated periodon-
tally according to a variety of different approaches [9, 23, 
25], we did not expect to see significant differences in the 
non-radiographic periodontal clinical parameters like 
PPD reduction or PAL gain in the current small sample 
of smokers followed, instead CADIA was chosen as the 
dependent variable.
In general, despite having severe periodontitis, the 
smokers in the current study exhibited favorable initial 
periodontal healing in response to non-surgical peri-
odontal therapy, as exemplified by the reduction in their 
PPD and PAL, which were similar to those reported pre-
viously [9]. The favorable clinical responses observed in 
this case were comparable with those reported in previ-
ous studies regarding non-surgical therapy in smokers [9, 
38, 39].
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Similar to the results of an earlier report [40], our con-
trol group of smokers exhibited only minor changes in 
their amount of radiographic bone density at 12 months 
after the commencement of non-surgical periodontal 
therapy compared with the baseline. In contrast, the test 
participants appeared to maintain the initial bone den-
sity gained after the non-surgical periodontal therapy 
(Fig. 5d). mYJ could therefore maintain the radiographic 
bone density gained after the non-surgical periodontal 
therapy for up to 12  month after the commencement 
of treatment. The control medication, however, did not 
maintain the radiographic bone density of the smokers 
11 months after the periodontal therapy.
An un-blinded study by Luo et al. [41] used a 1 month, 
twice-daily CM recipe containing 12 different ingre-
dients, including gypsum fibrosum, Radix et Rhizoma 
Rehmanniae, Rhizoma Anemarrhenae and Cortex Phel-
lodendri as an adjunctive therapy in a 3-month clini-
cal trial involving non-surgical periodontal therapy on 
twenty 40–50-year-old females (test group). The con-
trol group received non-surgical periodontal therapy 
without any placebo agent. The authors did not profile 
the CM status of their participants before and after the 
study period. Except for a lower BOP % value in the test 
group at 3 months, the changes in the PAL and PPD val-
ues between the two groups were not significant over the 
study period. One earlier study compared the twice-daily 
oral administration of a 4  mg dose of Guchi pills over 
3 months (n = 50) with the four-times daily administra-
tion of an oral 200  mg dose of spiramycin over 5  days 
(n = 40) as adjunctive agents to non-surgical periodon-
tal therapy [37]. Guchi pill contains 18 different ingre-
dients, including Radix et Rhizoma Rehmanniae, Radix 
Achyranthis Bidentatae and Rhizoma Drynariae, which 
are three of the eight active ingredients of mYJ. The study 
monitored the participants for 24 months after the initia-
tion of the study (i.e., the baseline). The authors reported 
that participants in the Guchi pills and spiramycin groups 
improved considerably. The 90 participants in this study 
consisted of a mixture of aggressive and chronic peri-
odontitis patients with mild-to-severe disease at presen-
tation and varied CM syndromes at baseline, including 
28 % with SH and KYD. Unfortunately the authors pre-
sented limited clinical information, making it difficult to 
establish the true efficacy of the CM preparation or the 
spiramycin as adjunctive agents in non-surgical peri-
odontal treatment.
With reference to the literature, purified or enriched 
extracts from the ingredients of the mYJ preparation used 
in this study have been independently reported to posi-
tively affect bone density in laboratory animals and cell 
cultures. For example, Rehmanniae has been reported to 
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Fig. 4 Proportion of participants with CM stomach‑heat syndrome 
and/or kidney‑yin deficiency over the study period. a Stomach‑heat 
(SH) syndrome, b Kidney‑yin deficiency (KYD), c combined stomach‑
heat and kidney‑yin deficiency, Dashed line placebo group; solid line 
mYJ group. *P < 0.05, **P < 0.001, control vs. test group at corre‑
sponding time point, Fisher exact test. Significant improvement of 
stomach‑heat, kidney‑yin deficiency alone in test or placebo group or 
stomach‑heat and/or kidney‑yin deficiency in test group over time was 
observed (Chi square test for trend, P < 0.001); no such improvement 
could be observed in control group when combined stomach‑heat 
and/or kidney‑yin deficiency was followed over time (c)
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stimulate the proliferation of osteoblasts [42]; Rhizoma 
Anemarhenae [43] and Drynariae Rhizoma [44] have 
been reported to promote bone formation; and Achyran-
this bidentatae [45] and Puerariae radix [46] have been 
reported inhibit bone loss. The remaining ingredients of 
mYJ including Phellodendri cortex and Ophiopogonis root 
have been reported to attenuate bacterial lipopolysaccha-
ride-induced inflammation [47] and protect frog palatal 
epithelial cells against sodium metabisulphite induced 
damage [48], respectively. The major alkaloid component 
of Phellodendri cortex, berberine, has been reported to 
modulate the post-transcriptional regulatory mecha-
nism of the iNOS gene, inhibit the activity of COX-2 and 
reduce the production of PGE2 in LPS-stimulated mouse 
macrophages [49]. Cortex Phellodendri and rhizome 
Rehmanniae have been shown to inhibit Porphyromonas 
gingivalis in  vitro [50]. The major ingredients in mYJ 
could potentially attenuate periodontal inflammation and 
promote bone healing.
The control flavoring agent: Momordica Charantia 
despite having CM heat clearing alleviation of dental pain 
plus hypoglycemic effects [51], was not reported to possess 
bone cell stimulation functions. The dose and duration use 
of Momordica Charantia administered could not clear the 
SH of all the periodontitis-affected male smokers.
The fact that 64–73  % of the mYJ group participants 
remained free from SH and/or KYD syndromes after the 
6-month recall in the study indicated that mYJ was effec-
tive in alleviating the corresponding syndrome in these 
smoking periodontitis individuals. The reason why 3-to-4 
mYJ group participants continued exhibiting SH and/or 
KYD syndrome, remains to be elucidated.
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The mYJ formula might maintain the improved alveolar 
bone density from the immediate post-treatment stage 
up to 12  months, while the positive hard tissue effects 
detectable on radiographs at selected sites with placebo 
adjunctive to non-surgical periodontal therapy could 
only be maintained over the first 6 months. By 9 months, 
radiographic bone densities of control sites had reverted 
to the pre-treatment levels.
Conclusions
The adjunctive use of mYJ preserved the post-treatment 
increases in the radiographic alveolar bone density at the 
study sites and led to an overall improvement in SH and 
KYD compared with the controls.
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